Crm. Clindax
Vaginal Cream · Vaginal · 2% / vaginal cream · 20 gm
৳70.26
Crm.
Clindax
Clindamycin (Vaginal Cream)
— Opsonin Pharma Ltd.
2% / vaginal cream
· 20 gm
Presentation
Dose rules
No structured dose rules are linked to this brand yet.
Dose reference
Human
One applicator full (approximately 5 gram) intravaginally at bedtime for 7 consecutive days. In patients in whom a shorter treatment course is desirable, a 3-day regimen has been shown to be effective.
Clinical notes
Applications:
- Bacterial vaginosis
Indication Notes:
Clindamycin cream is indicated in the treatment of bacterial vaginosis. Clindamycin cream can be used to treat non pregnant women and pregnant women during the second and third trimester.
Avoid In:
N/A
Contraindication Notes:
Clindamycin cream is not recommended in children under 12 years of age.
Clindamycin Phosphate is a water soluble ester that derived from the parent antibiotic Lincomycin. Clindamycin inhibits bacterial protein synthesis by binding preferentially to the 50s ribosomal subunit and affects the process of peptide chain initiation. In vitro Clindamycin is active against most strains of the following organisms that have been reported to be associated with bacterial vaginosis: Bacteroides spp. Gardnerella vaginalism Mobiluncus spp. Mycoplasma hominis Peptostreptococcus spp.
Clindamycin may results the following side effects. Genital tract: vaginitis, vulvo-vaginal irritation Central nervous system: dizziness, headache, vertigo.Gastro-intestinal: heartburn, nausea, vomiting, diarrhea, constipation, abdominal pain. Dermatological: rash, exanthema. Hypersensitivity: urticaria.
Intravaginal overdose is not possible. Accidental ingestion of the product could be accompanied by effects related to therapeutic levels of oral clindamycin.
There are no adequate and well-controlled studies in pregnant women during the first trimester of pregnancy. This drug should be used during the first trimester of pregnancy only if clearly needed. There is no restriction to use Clindamycin cream during the second and third trimester. It is not known if clindamycin is excreted in breast milk following the use of vaginally administered Clindamycin phosphate. However, orally and parenterally administered Clindamycin has been reported to appear in breast milk.
The patient should be instructed not to engage in vaginal intercourse, or use other vaginal products during treatment with this product. This cream contains mineral oil that may weaken latex or rubber products such as condoms or vaginal contraceptive diaphragms. Therefore, use of such products within 72 hours following treatment with Clindamycin cream is not recommended.